Shares of WUXI APPTEC Co., Ltd (02359.HK) soared 16.21% on Thursday amid reports that the Chinese biotech firm and its related companies are exploring the divestment of certain assets in response to potential U.S. restrictions.
According to a Financial Times report, WUXI APPTEC is considering selling its WUXI Advanced Therapies unit, which manufactures cell and gene therapies and has operations in the United States. The report, citing sources familiar with the matter, also indicated that WUXI Biologics is gauging interest in its European production facilities.
The reported asset sale plans come as the U.S. House of Representatives recently passed a draft of the Biosecure Act, which designates the WUXI companies as "biotechnology companies of concern" due to alleged military ties. If enacted, the legislation could bar U.S. government agencies from using funding or making contracts that involve certain biotechnology equipment or services from designated companies like WUXI.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。